Canadian Patients With Axial Spondyloarthritis Require Almost a Decade To Be Diagnosed Leading to Severe Functional Limitation. Results From the International Map of Axial Spondyloarthritis (IMAS)
Diagnostic delay continues to be a barrier to optimal care for Canadian axSpA patients. Significant diagnostic delay, associated with a high number of HCP visits prior to diagnosis, high use of NSAIDs, and marked functional limitation in daily life, illustrate the convoluted axSpA patient journey.
Authors
- J. Correa-Fernández
- Michael G. Mallinson
- Marco Garrido‐Cumbrera (ORCID: https://orcid.org/0000-0001-9727-1189)
- Robert D. Inman (ORCID: https://orcid.org/0000-0002-4750-1422)
- Sherry Rohekar (ORCID: https://orcid.org/0000-0001-8949-4198)
- Nigil Haroon (ORCID: https://orcid.org/0000-0003-3210-4771)
- Proton Rahman (ORCID: https://orcid.org/0000-0002-4521-2029)
- Elie G. Karam (ORCID: https://orcid.org/0000-0002-4681-8225)
- Jonathan Chan (ORCID: https://orcid.org/0000-0002-1837-5340)
- Jeremy Beach (ORCID: https://orcid.org/0000-0002-8788-8406)
- A. Jovaisas (ORCID: https://orcid.org/0000-0003-4887-0980)
- Patrick Leclerc
- Artur J. de Brum‐Fernandes
- Martin Cohen
Institutions
- Western University (CA)
- Memorial University of Newfoundland (CA)
- University Health Network (CA)
- Université de Sherbrooke (CA)
- University of British Columbia (CA)
- University of Ottawa (CA)
- University of Toronto (CA)
- Canadian Standards Association (CA)
- Novartis (Canada) (CA)
- Universidad de Sevilla (ES)
Publication Details
- Journal
- Musculoskeletal Care
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/msc.70010
- Citations
- 1
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Novartis
- Novartis Pharma